Latest news with #CloverHealthInvestments
Business Insider
09-08-2025
- Business
- Business Insider
Leerink Partners Reaffirms Their Hold Rating on Clover Health Investments (CLOV)
In a report released today, Whit Mayo from Leerink Partners maintained a Hold rating on Clover Health Investments, with a price target of $2.50. The company's shares closed today at $2.18. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Mayo covers the Healthcare sector, focusing on stocks such as Tenet Healthcare, Universal Health, and Ardent Health Partners, Inc.. According to TipRanks, Mayo has an average return of 0.3% and a 45.48% success rate on recommended stocks. In addition to Leerink Partners, Clover Health Investments also received a Hold from UBS's Jonathan Yong in a report issued on August 6. However, yesterday, Canaccord Genuity maintained a Buy rating on Clover Health Investments (NASDAQ: CLOV).
Yahoo
11-07-2025
- Business
- Yahoo
Clover Health Investments (CLOV) Announces Launch of a New Community-Based Pharmacy Pilot Program across New Jersey
Clover Health Investments, Corp. (NASDAQ:CLOV) is one of the 13 Best Healthcare Stocks to Buy Under $10. On July 9, Clover Health Investments, Corp. (NASDAQ:CLOV) announced the launch of a new community-based pharmacy pilot program across New Jersey, built in partnership with IPC Digital Health. An older Medicare-eligible consumer smiling happily while receiving healthcare services at a clinic. The initiative aims to help seniors in managing their medications and improve their health at home, supported by the local pharmacies they trust and know. Clover Health Investments, Corp. (NASDAQ:CLOV) stated that IPC's iCare+ Independent Pharmacy Network would anchor the program, which covers thousands of community-rooted pharmacies across the nation and several in New Jersey. Leveraging virtual services and innovative care tools, these local pharmacies would eliminate the need for unnecessary hospital visits by helping Clover members living with chronic conditions manage and stay on track with their medications. Clover Health Investments, Corp. (NASDAQ:CLOV) is a physician enablement technology company that offers Medicare Advantage plans in the United States. It offers PPO and HMO Medicare Advantage plans in several US states. While we acknowledge the potential of CLOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-04-2025
- Business
- Yahoo
Is Clover Health Investments, Corp. (CLOV) the Best Multibagger Penny Stock to Buy According to Billionaires?
We recently published a list of . In this article, we are going to take a look at where Clover Health Investments, Corp. (NASDAQ:CLOV) stands against other best multibagger penny stocks to buy according to billionaires. Penny stocks always seem like bargains for gaining exposure to some of the fastest-growing segments or spectacles, especially when popular stocks cost hundreds or thousands of dollars. Given that some cost as little as $2, they can be tempting for growing money quickly without spending much. While it's possible to achieve significant returns while investing in companies with depressed stock prices, caution is always of utmost importance. Low-priced stocks come with elevated levels of volatility as reduced liquidity makes them speculative, high-risk investments. Over the years, massive penny-stock scams have cheated thousands of investors out of millions of dollars, even as others have generated a fortune out of them. 2024 was one such year where investors betting on penny stocks generated a fortune as the overall stock market remained bullish. Explosive gains came into play as the equity outlook improved on expectations that the US Federal Reserve would cut interest rates. Amid the current correction in the equity market after two years of blockbuster gains, penny stocks are increasingly becoming popular owing to their depressed valuations. President Donald Trump's eldest son, Donald Trump Jr., and Lara Trump have already joined the fray in acquiring significant stakes in a conservative radio network, affirming renewed interest in thinly traded companies. Nevertheless, in the face of rising trade tensions and the lowest consumer confidence seen in almost three years, US markets have faced significant fluctuations. Yet, despite these obstacles, the idea of penny stocks continues to hold relevance as investors hunt for low-cost options with potential for growth. Often linked with smaller or emerging companies, these stocks can present considerable upside when supported by robust financials and sound fundamentals. It is possible to realize impressive returns by investing money into young firms with small market valuations or undervalued stock prices. That is especially the case at a time when President Trump is increasingly pushing for lower interest rates in the US. Like large-cap stocks, penny stocks tend to do well in low-interest rates environments as acquiring capital to accelerate operations and generate shareholder value becomes easier and more affordable for new and emerging companies. For this article, we used a stock screener first to identify stocks priced under $5 that have posted huge gains over the past year (at least 100%). From the obtained dataset, we selected penny stocks with the highest percentage gains in stock performance over the past year (as of April 21). The list is ranked based on the number of billionaires that hold stakes in them, the data for which we sourced from Insider Monkey's proprietary database. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). An older Medicare-eligible consumer smiling happily while receiving healthcare services at a Health Investments, Corp. (NASDAQ:CLOV) is a healthcare company that provides Medicare Advantage plans. Using a data-driven approach, it offers preferred provider organization and health maintenance organization plans to Medicare-eligible individuals. The stock has rallied by about 480.65% over the past year as investors react to a significant growth in its Medicare Advantage membership. While membership has surpassed the 100,000 level, Clover Health Investments, Corp. (NASDAQ:CLOV) has also seen its flagship PPO plan upgraded with a 4-star rating by the Centers for Medicare and Medicaid Services. The robust membership growth was the catalyst behind the company delivering a 9% increase in insurance revenue to $1.3 billion. Clover Health achieved profitability in full-year 2024, with EBITDA rising by $112 million to reach $70 million. Clover Health Investments, Corp. (NASDAQ:CLOV) expects the underlying growth to continue in 2025 as it projects a 30% year-over-year increase in Average Medicare Advantage membership. It also expects insurance revenue to be between $1.8 and $1.875 billion. On April 8, Canaccord Genuity reaffirmed a Buy rating and a $4.50 price target for Clover Health (NASDAQ:CLOV), citing strong growth prospects and sector sentiment improvement. Clover Health's robust performance, boosted by 4-Star rating reimbursements and revenue growth, positions it well for future expansion in 2026. Overall, CLOV ranks 5th on our list of best multibagger penny stocks to buy according to billionaires. While we acknowledge the potential of CLOV as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than CLOV but that trades at less than 5 times its earnings check out our report about the . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
